Turkey HIV Therapeutics Market Analysis Report [2022-30]

Turkey HIV Therapeutics Market Analysis

$ 3999

The Turkey HIV therapeutics market is expected to reach $141.63 Mn by 2030, up from $110.08 Mn in 2022, with a CAGR of 3.2 % from 2022 to 2030. Local players such as Abdi İbrahim, Pharmactive, and Deva Holding dominate the HIV therapeutics market in Turkey. Government policies, funding, and initiatives to manage HIV infections in the country propel market growth. The HIV therapeutics market in Turkey is divided into four segments: type, product, geography, end user, and distribution channel.

ID: IN10TRPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Turkey AUTHOR: Dr. Vishwa Modhia

Buy Now

Turkey HIV Therapeutics Market Analysis Summary

The Turkish HIV therapeutics market is expected to reach $141.63 Mn by 2030, up from $110.08 Mn in 2022, with a 3.2 % CAGR from 2022 to 2030.

Turkey is a transcontinental country bordering the Black Sea in Southeast Europe and Southwest Asia. According to the most recent WHO data published in 2020, the number of HIV/AIDS deaths in Turkey reached 204, accounting for 0.05 % of all deaths. Turkey ranks 142nd in the world with an age-adjusted death rate of 0.24 per 100,000 population. Red Ribbon Istanbul is a “civil society organization” that aims to raise awareness and provide information on HIV to be shared, focusing mainly on people living in İstanbul in various segments of the population.

Turkey is obligated to establish an effective HIV surveillance system. In 2013, the WHO proposed a new treatment protocol (option B+) to prevent HIV transmission from mother to child. In 2020, Turkey will spend 4.6 % of its GDP on healthcare.

turkey HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers

According to OECD figures, Turkey's per capita healthcare spending has reached $857, a 3.5-fold increase since 2002, when the healthcare transformation program was launched. In addition, in response to the sharp increase in HIV cases, Turkey increased awareness campaigns in universities. There were no additional details provided. Turkey is also opening more health centers where people can get free HIV blood tests and counseling on treatment and support services. These factors may encourage new entrants into Turkey's HIV therapeutics market.

Market Restraint

Every year, approximately 100 HIV-positive people in Turkey develop AIDS. This demonstrates Turkey's poor management and treatment of HIV infection. According to activists and the Health Ministry, the reasons for the sharp increase in HIV cases vary, but the main cause is unprotected sex, with contraception prevalence at around 60%. These factors may deter new entrants into the Turkish HIV therapeutics market.

Competitive Landscape

Key Players

Deva Holding (TUR)
Pharmactive (TUR)
Abdi İbrahim (TUR)
Nobel İlaç (TUR)
Gilead Sciences
AbbVie
Roche

Recent Notable Updates

June 2022: With its vision of "In Turkey for Turkey," Gilead, which began domestic production in collaboration with its partner Pharmactive, will be able to contribute roughly 70% of the volume of domestic products. The company will produce innovative medicines in the fields of Hepatitis and HIV in Turkey with this $60 Mn localization investment, which has been identified by the World Health Organization (WHO) as the diseases for which access to drugs is most critical. Turkey has become one of the world's newest production bases for the most innovative and life-saving medicines.

Healthcare Regulations and Reimbursement Policies

The Turkish Medicines and Medical Devices Agency (TİTCK) is the regulatory body in Turkey responsible for the approval and oversight of medicines, including HIV therapeutics. The TTCK is in charge of evaluating and approving applications for marketing authorization for medicines, as well as monitoring and enforcing regulatory compliance. The TİTCK is responsible for implementing national regulations and guidelines for medicines in Turkey and reports to the Ministry of Health.

The Social Security Institution (SGK) in Turkey is the primary body in charge of reimbursing the costs of healthcare services and medications, including HIV therapeutics. Under the Ministry of Health, SGK is in charge of providing medical expense coverage to insured individuals in Turkey, including both Turkish citizens and foreign residents. The SGK is also in charge of determining reimbursement rates for healthcare services and medications, including HIV therapeutics, as well as implementing healthcare financing and reimbursement policies.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.